No Data
No Data
New Analyst Forecast: $ACTU Given $21.0 Price Target
Craig-Hallum Initiates Actuate Therapeutics(ACTU.US) With Buy Rating, Announces Target Price $21
Craig-Hallum Bullish on Actuate Therapeutics, Initiates With a Buy
Actuate to Present Promising Data on Elraglusib in Advanced Salivary Gland Carcinoma at the AACR Annual Meeting 2025
Express News | Actuate Therapeutics Inc - Have the Right to Sell up to $50 Million Newly Issued Shares - SEC Filing
Express News | Actuate Therapeutics Inc - Enters Stock Purchase Agreement With B. Riley Principal Capital II, LLC - SEC Filing